The last 20 years is one of the most remarkable periods in the fight against cancer, with the realization that some human papillomaviruses are causally related to cancer and with the development of ...the vaccine against human papillomavirus infections. This is a historical event in medicine and the prophylactic human papillomavirus vaccines have provided powerful tools for primary prevention of cervical cancer and other human papillomavirus-associated diseases. This is very important as human papillomavirus infection is probably the most common sexually transmitted infection worldwide, and over one million women develop associated cancer yearly, which is about 5% of all female cancers, and half of them die of their disease. Cancers associated with oncogenic human papillomaviruses, mostly HPV16 and 18, include cervical cancer (100%), anal cancer (95%), vulvar cancer (40%), vaginal cancer (60%), penile cancer (40%), and oro-pharingeal cancers (65%). In addition, pre-cancers such as genital warts and the rare recurrent respiratory papillomatosis are also preventable by vaccination. Currently, the human papillomavirus vaccines have the potential to significantly reduce the burden of human papillomavirus associated conditions, including prevention of up to 70% of cervical cancers. Two prophylactic human papillomavirus vaccines are currently available worldwide: a bivalent vaccine (types 16 and 18), and a quadrivalent vaccine (types 6, 11, 16, and 18). Randomized controlled trials conducted on several continents during the last 10 years have demonstrated that these vaccines are safe without serious side effects; they are highly immunogenic and efficacious in preventing incident and persistent vaccine-type human papillomavirus infections, high grade cervical, vulvar and vaginal intraepithelial neoplasia and so on. In addition, the quadrivalent vaccine has been shown to prevent genital warts in women and men. The vaccine is most effective when given to human papillomavirus naive girls. The human papillomavirus vaccines have been incorporated into national immunization programs in 22 European countries. Routine vaccination is recommended for girls aged between 9 and 13 years and catch-up vaccination for females between 13 and 25 years of age. There is no excuse not to incorporate the vaccines into the Hungarian national immunization program. Albeit vaccination is expensive, it is cost-effective in the long run definitely. Anyway, vaccination is a matter of the specialty and the national health program, but not of business. We all are obliged to prevent human suffering.
Hungarian language medical journals were published only since the 19th century. The first one among them was the Medical Magazine founded and edited by Pál Bugát and Ferenc Schedel Toldy in 1831. ...Unfortunately, it ceased to exist after the freedom fight 1848-49. One decade after the bloody defeating of the freedom fight founded Lajos Markusovszky the Orvosi Hetilap 1857 that was issued without a break to our days. This is the world’s seventh oldest medical journal a proud part of the Hungarian Heritage as well. Specialists published first in the supplements of the journal and the Gyógyászat founded by Imre Poór separated first from the original paper. At the end of the century, there were published already specific journals of many specialities. These journals mirrored exactly the development of Hungarian medical language. The Orvosi Tár revealed obviously all difficulties of creating new medical terms. However, the Orvosi Hetilap used already exact Hungarian definitions. It is almost unbelievable how precisely the authors wrote their articles. Only since the second half of the 20th century were emerging terms of foreign origin, initially Greco-Latin and later on the rapidly spreading English.
PDF
